ArticleScientific reports2026
Analytical validation of aldolase, microalbumin and myeloperoxidase in canine saliva and their evaluation in canine gingivitis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Saliva is a biological fluid that offers potential practical advantages for biomarker assessment in dogs due to its non-invasive nature. This study evaluated aldolase (ALS), microalbumin (mALB), and myeloperoxidase (MPO) in canine saliva using automated assays. All assays showed acceptable analytical performance, with adequate precision (coefficients of variation < 15%), accuracy (coefficients of determination close to 1 after serial sample dilutions), and sensitivity (lower limits of quantification of 5.6 IU/L, 2.05 mg/dL, and 26.3 IU/L for ALS, mALB and MPO, respectively). The effect of gingivitis on these salivary analytes was also assessed. Dogs with gingivitis showed significantly higher salivary ALS and mALB results — ALS, 21.9 (14.2–37.3) IU/L; mALB, 13.15 (5.89–25.71) mg/dL — compared with controls — ALS, 7.65 (2.2-12.23) IU/L; mALB, 3.51 (2.32–5.21) mg/dL— (p < 0.0001). Moreover, increasing gingivitis severity was associated with progressively higher levels of ALS and mALB. In contrast, no significant differences were observed in MPO activity between groups. These findings suggest that ALS and mALB may serve as salivary biomarkers for gingivitis assessment. Further studies are warranted to explore their potential applicability in other local and systemic inflammatory conditions in dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.